SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Avalanche is a high throughput smart contract blockchain&nbsp;platform. Validators secure the network through a proof-of-stake consensus protocol. It is said to be fast, low cost, and environmental friendly.

Avalanche

A sharp AVAX rebound and heavier trading activity have fueled renewed attention, with traders linking the move to institutional and real-world-asset adoption narratives, including reported NYSE tokenization testing and expanded brokerage access. Bulls view the rally as a breakout and altcoin rotation, while skeptics call it another pump-and-dump with weak follow-through and persistent selling pressure.

StarkNet is a permissionless decentralized Layer 2 (L2) validity rollup, built to allow Ethereum to scale via cryptographic protocols called STARKs, without compromising Ethereum’s core principles of decentralization, transparency, inclusivity and security. The StarkNet Token is needed to operate the ecosystem, maintain and secure it, decide on its values and strategic goals, and direct its evolution. This token will be required for (i) governance, (ii) payment of transaction fees on StarkNet, and (iii) participation in StarkNet’s consensus mechanism.

Starknet

Starknet is generating significant buzz as it pivots toward an ambitious privacy and institutional-grade DeFi roadmap, underscored by the upcoming launch of strkBTC and native privacy upgrades. Community discussions are heavily centered on the project's 'ZK-first' architecture, its status as a quantum-resistant scaling solution, and its growing strength in developer activity, which many users view as a bullish signal for long-term utility despite recent market volatility.

TRON is a decentralized blockchain-based operating system designed to accelerate the decentralization of the internet and its underlying infrastructure. It serves as a global settlement layer for stablecoins and everyday digital purchases, providing a high-throughput environment to support large-scale decentralized applications. The network is governed by a decentralized autonomous organization (DAO), which allows the community to manage the protocol without a central authority. Its primary value proposition includes a unique resource model that utilizes bandwidth and energy to allow for high transaction volumes without traditional fee spikes.  The platform functions as a smart contract platform that enables the creation of decentralized applications and is compatible with the Ethereum Virtual Machine, allowing developers to easily migrate applications. TRON operates using a Delegated Proof of Stake consensus mechanism where token holders vote for 27 Super Representatives to verify transactions and maintain the ledger. This structure is built for scalability and fast finality, aiming to handle more transactions per second than many established legacy blockchains. Users can interact with the ecosystem for various purposes, including decentralized finance (DeFi) through platforms like JustLend DAO and decentralized storage via the BitTorrent File System.  Value moves through the system via its native utility token, TRX, which facilitates transactions and grants users access to network resources. Holders can lock their TRX in a staking mechanism to gain TRON Power, which is used to vote on network rules and elect Super Representatives, earning rewards for securing the network. Established by the TRON Foundation and led by founder Justin Sun, the project has transitioned into a community-led DAO. The ecosystem is supported by strategic partnerships with major global entities, including Samsung, which integrated TRON into its blockchain keystore, as well as BitTorrent, Opera, and Swisscom Blockchain.

Tron

TRON is drawing attention for its relative resilience and technical breakout, with traders highlighting steady upward momentum and strength while other major altcoins weaken. The community is broadly bullish on continued gains, though some technical views still call for consolidation or a corrective pullback; stablecoin payment activity is cited as fundamental support.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

A volatile rebound in PEPE alongside broader crypto strength is driving attention, with traders attributing the move to short-covering, liquidations, and a possible technical breakout. Bullish participants are discussing accumulation and further upside, while others characterize the move as low-volume speculation or a pump-and-dump and warn of a pullback.

Venice boasts an innovative approach to generative AI with its unique privacy architecture, access to competitive features including multiple leading open-source LLM models such as DeepSeek R1, PDFs analysis, and image and code generation. An unrestricted AI Characters feature is available with its Pro version, Venice Pro.   VVV is designed to minimize friction and reduce costs for AI agents and developers to access private, reliable, on-demand and perpetual AI inference via Venice.ai's API.

Venice Token

Venice Token is trending as investors respond to major platform updates including the v4 launch and a shift toward an active buy-and-burn model, which many believe will drive long-term supply scarcity. The community is heavily focused on the project's pivot toward an agentic AI ecosystem, with many debating the impact of recent revenue-sharing incentives and staking dynamics on its potential to retest all-time highs.

The Kraft Heinz Co. engages in the manufacture and market of food and beverage products. It operates through the North America and International geographical segments. The company was founded on July 2, 2015, and is headquartered in Pittsburgh, PA.

Kraft Heinz Co

Kraft Heinzs move from Nasdaq to the NYSE coincided with unusually heavy trading volume, prompting speculation about index-fund repositioning, short selling, and possible market manipulation. Traders are divided between viewing the activity as a technical opportunity and focusing on the companys dividend and potential turnaround despite ongoing concerns about weak fundamentals.

Wingstop, Inc. is a franchisor and chicken wings-focused restaurant. The firm is engaged in the flavor business offering cooked-to-order, hand-sauced, and tossed classic and boneless wings, tenders and chicken sandwiches in flavors, with signature sides, such as its seasoned fries and house made ranch and bleu cheese dips. The company was founded in 1994 and is headquartered in Dallas, TX.

Wingstop Inc

Weak comparable-store sales and broader concerns about consumer spending, inflation, and fuel costs are driving Wingstops sharp selloff alongside other restaurant stocks. Traders remain divided, with bears warning of further downside while bulls view the decline as an oversold opportunity supported by franchise-led unit growth and long-term expansion.

PepsiCo, Inc. engages in the manufacture, marketing, distribution, and sale of beverages, food, and snacks. It operates through the following business segments: PepsiCo Foods North America (PFNA), PepsiCo Beverages North America (PBNA), International Beverages Franchise (IB Franchise), Europe, Middle East and Africa (EMEA), Latin America Foods (LatAm Foods), and Asia Pacific Foods. The PFNA segment refers to the food businesses in the United States and Canada. The PBNA segment includes beverage businesses in the United States and Canada. The IB Franchise segment involves the international franchise beverage businesses, as well as the SodaStream business. The EMEA segment pertains to food businesses and beverage businesses with company-owned bottlers in Europe, the Middle East, and Africa. The LatAm Foods segment consists of food businesses in Latin America. The Asia Pacific Foods segment is associated in food businesses in Asia Pacific, including China, Australia and New Zealand, as well as India. The company was founded by Donald M. Kendall, Sr. and Herman W. Lay in 1965 and is headquartered in Purchase, NY.

PepsiCo Inc

Mixed quarterly results and a cautious North American consumer outlook have pushed PepsiCo toward multi-year lows, with traders citing weaker snack demand, margin pressure, inflation and GLP-1 usage as ongoing concerns. Bulls view the selloff as an attractive dividend-led value opportunity, while bears argue the weakness reflects a deeper deterioration in growth and capital allocation.

Grayscale Investments LLC - Grayscale Zcash ETF

Grayscale Zcash Trust ZEC

Grayscales announced 3-for-1 share split is driving attention to ZCSH, with traders viewing the lower entry price and improved liquidity as supportive for access to Zcash exposure amid a strong ZEC rally. Sentiment is broadly bullish, though some debate whether the trust is lagging or trading at a premium/discount to its underlying holdings has prompted profit-taking and caution.

CorMedix, Inc. is a pharmaceutical and medical device company, which engages in the development and commercialization of therapeutic products for the prevention and treatment of diseases and conditions. The company was founded by Antony E. Pfaffle on July 28, 2006 and is headquartered in Berkeley Heights, NJ.

CorMedix Inc

A new multi-year DefenCath supply agreement with DaVita, completing contracts with the five largest U.S. dialysis providers, alongside a quarterly beat and higher adjusted EBITDA outlook, is driving attention. Traders remain divided over whether the contract can offset post-TDAPA reimbursement pressure, with limited 2027 guidance and the timing of the REZZAYO sNDA adding uncertainty.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Turn Therapeutics to Present at Stifel 2026 Virtual Immunology and Inflammation Forum

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced that Bradley Burnam, Chief Executive Officer, and Stephen M. Hahn, M.D., Executive Clinical and Regulatory Lead, will present at the...

Turn Therapeutics Appoints Former CDC Director Robert R. Redfield, M.D., as Chief Scientific Officer

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today announced the appointment of Robert R. Redfield, M.D., as Chief Scientific Officer. Dr. Redfield brings more than four...

Turn Therapeutics Announces New Peer-Reviewed Research Showing GX-03 Selectively Reduces Key Drivers of Skin Inflammation and Itch

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of new peer-reviewed research providing in-vivo evidence that its lead investigational therapy, GX-03...

Turn Therapeutics Provides Corporate Updates and Reports Second Quarter 2026 Financial Results

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory and infectious skin diseases, today provided corporate updates and reported financial results for the three and six months ended June 30, 2026. The second...

Turn Therapeutics to Ring the Nasdaq Closing Bell on Monday, August 10, 2026

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced that Bradley Burnam, Founder and Chief Executive Officer, will ring the Nasdaq Closing Bell on August 10, 2026, along with...

Why Is Turn Therapeutics Stock Trading Higher Today?

Turn Therapeutics expanded its GX-03 Phase 2 trial after interim data supported efficacy across a broader atopic dermatitis population.read more...

Turn Therapeutics Announces Final Stage 2 Design and Data-Driven Expansion of GX-03 Phase 2 Program in Atopic Dermatitis

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced the completion of a comprehensive interim analysis of its ongoing adaptive Phase 2 clinical trial evaluating GX-03 for the...

Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis

Turn Therapeutics, Inc. (NASDAQ: TTRX), a clinical-stage biotechnology company developing targeted, non-systemic therapies for inflammatory skin diseases, today announced it will host a live webcast on Tuesday, July 7, 2026, to present key findings from the comprehensive interim analysis of its...

Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company developing targeted, localized therapies for inflammatory skin diseases, today announced interim analysis findings from the first 50 completed subjects enrolled in its ongoing randomized, double-blind, vehicle-controlled...

Turn Therapeutics Announces Peer-Reviewed Publication in Journal of Dermatological Treatment Highlighting GX-03 Activity in IL-36 Associated Inflammatory Model

Turn Therapeutics Inc. (Nasdaq: TTRX), a clinical-stage biotechnology company focused on developing localized therapies for inflammatory and infectious skin diseases, today announced the publication of a peer-reviewed research article in the Journal of Dermatological Treatment evaluating the...

Turn Therapeutics, Inc. is a pharmaceutical and medical device development company. Its primary development programs focus on dermatological diseases. The company was founded by Bradley Burnam on January 6, 2015 and is headquartered in Westlake Village, CA.

Turn Therapeutics Inc.

Why Is Turn Therapeutics Stock Soaring Over 370% Premarket Today?

Equity

Bearish Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

TTRX Turn Therapeutics Inc

Fundamentals

Latest TTRX News